Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
Am J Physiol Cell Physiol. 2021 May 1;320(5):C669-C680. doi: 10.1152/ajpcell.00186.2020. Epub 2020 Dec 23.
Microphysiological systems (MPS), often referred to as "organ-on-chips," are microfluidic-based in vitro models that aim to recapitulate the dynamic chemical and mechanical microenvironment of living organs. MPS promise to bridge the gap between in vitro and in vivo models and ultimately improve the translation from preclinical animal studies to clinical trials. However, despite the explosion of interest in this area in recent years, and the obvious rewards for such models that could improve R&D efficiency and reduce drug attrition in the clinic, the pharmaceutical industry has been slow to fully adopt this technology. The ability to extract robust, quantitative information from MPS at scale is a key requirement if these models are to impact drug discovery and the subsequent drug development process. Microscopy imaging remains a core technology that enables the capture of information at the single-cell level and with subcellular resolution. Furthermore, such imaging techniques can be automated, increasing throughput and enabling compound screening. In this review, we discuss a range of imaging techniques that have been applied to MPS of varying focus, such as organoids and organ-chip-type models. We outline the opportunities these technologies can bring in terms of understanding mechanistic biology, but also how they could be used in higher-throughput screens, widening the scope of their impact in drug discovery. We discuss the associated challenges of imaging these complex models and the steps required to enable full exploitation. Finally, we discuss the requirements for MPS, if they are to be applied at a scale necessary to support drug discovery projects.
微生理系统(MPS),通常被称为“器官芯片”,是基于微流控的体外模型,旨在再现活体器官的动态化学和机械微环境。MPS 有望弥合体外和体内模型之间的差距,并最终提高从临床前动物研究到临床试验的转化。然而,尽管近年来人们对这一领域的兴趣大增,而且这些模型显然可以提高研发效率并减少临床药物淘汰率,但制药行业一直缓慢全面采用这项技术。如果这些模型要对药物发现和随后的药物开发过程产生影响,那么能够从 MPS 中大规模提取稳健、定量信息的能力是一个关键要求。显微镜成像仍然是一种核心技术,能够在单细胞水平和亚细胞分辨率下获取信息。此外,这种成像技术可以自动化,提高通量并实现化合物筛选。在这篇综述中,我们讨论了一系列已应用于不同焦点的 MPS 的成像技术,例如类器官和器官芯片型模型。我们概述了这些技术在理解机制生物学方面带来的机会,但也讨论了它们如何在高通量筛选中使用,从而扩大其在药物发现中的影响范围。我们讨论了对这些复杂模型进行成像的相关挑战,以及实现充分利用所需的步骤。最后,我们讨论了 MPS 的要求,如果要在支持药物发现项目所需的规模上应用的话。